<DOC>
	<DOCNO>NCT00891176</DOCNO>
	<brief_summary>This protocol post deal objective &amp; outcome measure extension phase subject age 3 , 4 6 year age . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT number = NCT00334334 ) . The objective &amp; outcome measure booster phase present separate protocol posting ( NCT number = NCT00463437 ) . The purpose study evaluate persistence pneumococcal , meningococcal serogroup C , Hib Hepatits B antibody booster vaccination , subject age 3 , 4 6 year . No vaccine administer persistence phase study .</brief_summary>
	<brief_title>Persistence Antibodies 3 , 4 6 Years Age After Vaccination With Meningococcal , Pneumococcal Hib Vaccines</brief_title>
	<detailed_description>This multicenter study open . No vaccine administer persistence phase study . The subject randomize primary vaccination study 107005 randomize study .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . A male female , include , 36 40 month age time Visit 1 ; , include , 48 52 month age time Visit 2 ; , include , 72 76 month age time Visit 3 . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Subjects previously participate primary booster study , receive full vaccination course vaccine correspond group primary booster study part , booster study , blood sampling subset . Use investigational nonregistered product ( drug vaccine ) within 30 day precede first blood sampling . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Administration additional meningococcal serogroup C , Hib , hepatitis B pneumococcal vaccine since end booster study History meningococcal serogroup C , Haemophilus influenzae type b , hepatitis B invasive pneumococcal disease since end booster study . Any confirm suspected immunosuppressive immunodeficient condition since end booster study , base medical history physical examination ( laboratory testing require ) . Administration immunoglobulins and/or blood product within three month precede first blood sampling .</criteria>
	<gender>All</gender>
	<minimum_age>36 Months</minimum_age>
	<maximum_age>76 Months</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Conjugate vaccine</keyword>
	<keyword>Meningococcal serogroup C vaccine</keyword>
	<keyword>Antibody persistence</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Haemophilus Influenzae type b vaccine</keyword>
</DOC>